| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.1M | -18.6% |
| SG&A Expense | $13.5M | -3.8% |
| Operating Income | -$27.6M | +12.0% |
| Pre-tax Income | -$25.5M | +15.3% |
| Income Tax | $0 | — |
| Net Income | -$25.5M | +15.3% |
| EPS (Basic) | -$0.20 | +16.7% |
| EPS (Diluted) | -$0.20 | +16.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $71.1M | -19.6% |
| Current Assets | $74.5M | -19.3% |
| Total Assets | $76.4M | -20.6% |
| Current Liabilities | $5.0M | -5.1% |
| Total Liabilities | $5.0M | -5.1% |
| Stockholders' Equity | $71.5M | -21.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$21.0M | -0.4% |
| Capital Expenditures | $19K | +35.7% |
| Investing Cash Flow | -$19K | -35.7% |
| Financing Cash Flow | $3.7M | +349.0% |
| Free Cash Flow | -$21.0M | -0.4% |